Mabtas 500 Mg Injection

About Mabtas 500 Mg Injection

Mabtas 500 mg Injection is a medication that contains Rituximab as its active ingredient. Rituximab is a monoclonal antibody used primarily in the treatment of certain cancers and autoimmune conditions. It works by targeting and depleting certain types of immune cells (B-cells) that may be contributing to disease processes.

Common Uses:

1. Cancer Treatment: Rituximab is often used for certain types of blood cancers, such as Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia (CLL), and Burkitt lymphoma.
2. Autoimmune Diseases: It's also used in the treatment of autoimmune conditions like rheumatoid arthritis and granulomatosis with polyangiitis (Wegeners granulomatosis).
3. Other indications: It may also be used for conditions like immune thrombocytopenic purpura (ITP) and some forms of vasculitis.

How it works:

Rituximab works by binding to a protein called CD20, found on the surface of B-cells. By binding to CD20, it triggers the immune system to destroy these B-cells, which can play a role in certain diseases like cancer and autoimmune conditions.

Common Side Effects:

• Fever, chills
• Low blood pressure
• Infections (due to reduced immunity)
• Rash, itching
• Nausea, vomiting
• Headache, dizziness

Important Considerations:

• Administered by Injection: Mabtas is usually administered intravenously in a healthcare setting under the supervision of a doctor or nurse.
• Pre-treatment Protocol: Prior to starting treatment, the doctor may perform tests to ensure that you are suitable for Rituximab therapy and to rule out any possible risks.
• Monitoring: Patients receiving Mabtas are typically monitored for infusion reactions, especially during the first infusion.

As always, it's important to follow your healthcare providers instructions and ask them any questions about the medication, especially about side effects or interactions with other treatments.

Advanced Immunotherapy for Multiple Indications

Mabtas 500 mg Injection leverages a biotechnologically-engineered monoclonal antibody to provide precise immunotherapy for a range of serious conditions, including certain cancers and autoimmune diseases. Its active ingredient, rituximab, targets specific cells, aiding in the management and remission of Non-Hodgkin's Lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, among others. Its proven efficacy and safety make it a trusted option in modern clinical practice.


Precision-Formulated and Convenient to Administer

Formulated as a sterile, ready-to-use solution, Mabtas is administered intravenously under strict medical supervision, ensuring both accuracy and patient safety. The colorless to pale yellow liquid is packaged in a portable vial for easy use in hospital and clinical settings. The vial's design supports simple preparation, while the solution's stability ensures optimal potency with storage instructions clearly outlined (2C - 8C, no freezing).